ÂÜÀòÂÒÂ×

Dr. David Bullough has over 25 years of pharmaceutical research and development experience, with a specialty in the development of small molecules and emerging new therapeutic modalities in multiple therapeutic areas. At Thesan, Dr. Bullough was the Head of Nonclinical Drug Development from 2016 to 2018. He previously served as the Chief Scientific Officer at Viking and was also an Executive Director at Pfizer, where he led multiple global therapeutic teams advancing metabolic disease candidates from discovery into early development. Dr. Bullough was also VP Preclinical Development at RaNA, a company developing new approaches to treating rare genetic central nervous system disorders. Dr. Bullough was previously VP of Preclinical Development at Metabasis, where he was responsible for Nonclinical Safety, DMPK, Bioanalytical, and Pharmaceutical Development, and for leading project teams developing novel drugs targeting the liver and liver pathways for the treatment of oncology, antiviral, and metabolic diseases. Prior to joining Metabasis, Dr. Bullough was with Gensia, where he managed Cardiovascular Pharmacology and led a number of major discovery and development projects. Dr. Bullough was a research faculty member at UCSD in La Jolla, CA and received his Ph.D. in Biochemistry from the University of Cambridge in the UK.